ArticleCancer medicine2020
Development of a prediction model with serum tumor markers to assess tumor metastasis in lung cancer.
Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- A pilot study of precision treatment for patients with lung cancer pain by Longteng Tongluo recipe using serum genomics.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2024Trial
- Integration of circulating biomarkers and clinical factors: construction and validation of a prediction model for lung cancer metastasis.BMC pulmonary medicine · 2025Article
- Prediction of Lung Cancer Metastasis Using Machine Learning Models Based on Clinical Laboratory Data.Cancer reports (Hoboken, N.J.) · 2025Article
- Beyond Carcinoembryonic Antigens: The Role of CA-125 and CA-199 in Predicting Prognosis of Lung Adenocarcinoma.Cancers · 2025Article
- MoLPre: A Machine Learning Model to Predict Metastasis of cT1 Solid Lung Cancer.Clinical and translational science · 2025Article
- The ratio of lymph node eluate/serum cytokeratin 21-1 is a potential predictor of lymph node metastasis in lung adenocarcinoma.Journal of thoracic disease · 2024Article
- Role of epithelial cell-mesenchymal transition regulators in molecular typing and prognosis of colon cancer.Journal of gastrointestinal oncology · 2023Article
- Diastole/Body Mass Index Ratio Can Predict Post-Thoracoscopic Surgery Metastasis in Stage I Lung Adenocarcinoma.Journal of personalized medicine · 2023Article
- Prognostic evaluation of preoperative serum tumor marker-negative cases in non-small cell lung cancer: A retrospective study.Cancer reports (Hoboken, N.J.) · 2023Article
- Assessment of circulating biomarkers for detection of lung cancer in a high-risk cohort.Cancer biomarkers : section A of Disease markers · 2023Article
- The Potential Role of MUC16 (CA125) Biomarker in Lung Cancer: A Magic Biomarker but with Adversity.Diagnostics (Basel, Switzerland) · 2022Review
- Role of circular RNAs in the diagnosis, regulation of drug resistance and prognosis of lung cancer.Oncology letters · 2022Review
- Identification of a novel DNA aptamer that selectively targets lung cancer serum.RSC advances · 2021Article
- Identification of prognostic factors and construction of a nomogram for patients with relapse/refractory adult-onset Still's disease.Clinical rheumatology · 2021Article
- Collagen type 1 alpha 1 chain is a novel predictive biomarker of poor progression-free survival and chemoresistance in metastatic lung cancer.Journal of Cancer · 2021Article
- Development of a prediction model with serum tumor markers to assess tumor metastasis in lung cancer.Cancer medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to explore the possibility of serum tumor markers (TMs) combinations in assessing tumor metastasis in patients with lung cancer.
methodsWe performed a retrospective analysis of 541 patients diagnosed with lung cancer between January 2016 and December 2017 at the Pneumology Department of Dazhou Central Hospital. Serum carcinoembryonic antigen (CEA), carbohydrate antigen (CA)125, CA153, CA199, CA724, cytokeratin 19 fragment (CYFRA), and neuron-specific enolase (NSE) levels were quantified in each patient at the time of lung cancer diagnosis. Metastasis was confirmed by computed tomography, and/or positron emission tomography, and/or surgery or other necessary methods. Receiver operating characteristic (ROC) curves and calibration curves were used to evaluate the performance of the model.
resultsOf the 541 patients eligible for final analysis, 253 were detected with metastasis and 288 were detected without metastasis. Compared with those in nonmetastatic patients, the serum CEA, CA125, CA199, CA153, CYFRA, and NSE levels were notably higher in metastatic patients (P < .05). The ROC curve demonstrated that the CEA-CA125-CA199-CA153-CYFRA-NSE-CA724 combination based on the cut-off value had an optimal area under the curve and specificity in assessing tumor metastasis. The decision tree model is a convenient and valuable tool for guiding the appropriate application of our model to assess metastasis in lung cancer patients.
conclusionsOur study suggested that the nomogram of the regression model is valuable for assessing tumor metastasis in newly diagnosed lung cancer patients before traditional standard methods are used. These findings could aid in the evaluation of metastasis in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.